2008 turned out to be an exciting and important year for completing large drug discovery milestones at Nutra Pharma.  As the year quickly comes to a close, I wanted to take a moment to reflect back on our top accomplishments…

Medical Devices

• We began developing and marketing through our medical devices subsidiary, Designer Diagnostics, the first-ever environmental test kit for the rapid detection of Nontuberculous Mycobacteria

Drug Discovery

• We acquired the remaining interest in our drug discovery holding, ReceptoPharm, which transitioned it into a Nutra Pharma wholly-owned subsidiary
• We received final approval from the Florida Department of Agriculture and Consumer Services to begin a trial using RPI-MN for treating Feline Leukemia Virus (FeLV). This study will not only help us develop a possible model for studying RPI-MN as a treatment for HIV in humans, but if successful, RPI-MN will be the first-ever treatment for FeLV, a virus that currently affects 2% to 3% of the cat population in the United States
• We successfully completed a 15-month Phase IIb/IIIa trial using RPI-78M as a treatment for Adrenomyeloneuropathy (AMN). We expect the fully-audited results from this study to be available in early 2009
• In addition to completing this Phase IIb/IIIa clinical trial, we also announced that initial reports and feedback from physicians involved with this study reported that patients had experienced no adverse side effects from RPI-78M. This led us to the decision to continue providing RPI-78M under compassionate release to patients previously enrolled in the study
• We renewed our collaborative agreement with the Centers for Disease Control and Prevention (CDC) to study RPI-78M and RPI-MN as a possible therapy for Rabies
• We received our first clinical drug supply contract from Celtic Biotech in Dublin, Ireland, which represented the first revenue for our drug discovery subsidiary, ReceptoPharm. As we continue into 2009, we plan to expand this outsourced drug production to additional biotechnology firms. This will allow us to fully utilize our GMP-qualified production facility and will also provide us with an additional revenue stream

Additional Outreach

• We re-launched our corporate blog to help build transparency between Nutra Pharma and those interested in our drug discovery research and corporate strategy
• We were mentioned in several articles published in various pharmaceutical industry trade publications
• We received an invitation by BlogBurst to extend the reach of our blog postings to be included in media outlets such as USA Today, Gannett, Reuters, FoxNews, Houston Chronicle and many others

For the past week, we have fielded several phone calls and emails asking us about the status of our clinical data for our Phase IIb study in treating Adrenomyeloneuropathy (AMN). While we are working diligently to get this information compiled, analyzed, and published as quickly as possible, it has taken a little longer than expected due to a lag in data collection from the last several patients in the Trial.

We understand how anxious and excited you are to learn more about the results of this trial. We are too! Please bear with us as we continue to process the data. We expect to have it available towards the end of October.

Update: November 17, 2008

The last patient’s visit occurred in August 2008 and currently, the data from the trial are being prepared for analysis, with results expected during early 2009.